Search
Evotec SE
EVOAdd to Watchlist
2.640USD
+0.080+3.13%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
938.06MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Evotec SE is 6.67, ranking 326 out of 389 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 7.00 and a low of 3.00.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
4.667
Target Price
+82.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Evotec SE
EVO
3
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Evotec SE's expected revenue for the next quarter?
Evotec SE's expected revenue is 204.83M.
What is Evotec SE's price target?
Analysts forecast that Evotec SE's price target is USD 5.00, with the highest forecast at USD 7.00 and the lowest forecast at USD 3.00.
How have Evotec SEEVO's recent earnings per share performed?
The market expectation was USD -0.40, while Evotec SEEVO's earnings per share (EPS) for the previous quarter was USD 0.05. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for Evotec SE?
Based on the ratings of Evotec SE's stock from 3 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.
